Beyond Stem Cells: Why You Won’t Die Until After 2225

If you have cancer or another heartbreaking disease or even fear you have a significant disease, my message to you today is:

HANG ON.

A revolution is underway in biotechnology and medicine.

This revolution will rival the Internet, the telephone and the Wright brothers’ first powered airplane flight.

It could point us to cures for most of humankind’s deadliest diseases and smooth the way to living for centuries, instead of decades. And it should be well underway by 2025. That’s just 10 short years away.

If you stay alive long enough, say another 10 or 20 years, most of today’s killer diseases may very well be curable.

But that won’t make you immortal.

I’m almost certain I know how you’ll finally die.

A 300-Year Life Span

Because even if we cure most diseases, you won’t be immortal. You’ll still be susceptible to an accident. Statistically, even if you seem immortal, you’re unlikely to live more than 300 years without encountering a fatal accident.

Not just car accidents, but all kind of accidents.

Nonetheless, I’ll bet you’d trade today’s average lifetimes for 300 years. Think about the possibilities. You could have 10 different careers. Obtain five different college degrees. Be a lawyer, an architect, an English professor and an artist all in one life.

As I said before, we are on the verge of extraordinary medical breakthroughs, and we can track the progress of this revolution by monitoring five critical fields.

They will be the benchmarks of a healthy life lasting centuries… and we are only a few years away from seeing them start to take hold.

The 5 Most Important Trends of 2015

Immunotherapy

Right now, scientists are developing a technology that can teach your body’s own immune cells to seek out and destroy cancerous tumors. There is one company that I believe is ahead of most others. And they have quietly but methodically locked up many of the patents applicable to their technology.

We own it in our Breakthrough Technology portfolio. It’s up 75% in less than three months because investors are beginning to figure out that it is likely to be successful. See the full write-up on this trend in Tomorrow in Review on Dec. 31, 2014.

Stem Cell Regeneration

Companies are racing to find ways to repair aging bodies with stem cells that can become any other kind of cells. Whether as a fix for macular degeneration, replacing dead heart cells after a heart attack or replacing spinal cord neurons, the idea behind the effort is solid. But stem cells have shown themselves to be difficult to manipulate and control. Turning on a so-called pluripotent stem cell to make it become a retina cell challenges our knowledge. Yet one company seems poised to make it happen. See the full write-up on this trend in Tomorrow in Review on Jan. 2, 2015.

Gene Editing

For years, editing genes in individual cells seemed impossible, even laughable. Yet if we crack the code, we can treat heart diseases that seem impossible to cure. Until recently, experiments in humans have failed. But that’s about to change. We have a company in our Breakthrough Technology Alert portfolio that is up 80% in three months because it is showing extraordinary promise in this area. See the full write-up on this trend in Tomorrow in Review on Jan. 5, 2015.

3-D Printing of Organs

What if you could replace any organ at any time without waiting for a donor? You could replace an aging heart… worn-out lungs and tired kidneys. It’s not as far-fetched as it sounds. We are on track to take your genome and print an organ your body will not reject because it’s not from someone else. See the full write-up on this trend in Tomorrow in Review on Jan. 7, 2015.

Better Testing of Drugs

There are a lot of drugs that have been pulled off the market in the last 20 years because despite rigorous FDA testing, they showed themselves to be toxic in the real world. We’re basically human guinea pigs for drug companies right now. But not for long. Into this void steps an unlikely stem cell company — General Electric. Its life sciences division has figured out how to test drugs for toxicity using human stem cells.

And they’ve just about convinced the FDA that no drug should be approved if it hasn’t been tested against the stem cell line.

In other words, you test the drug itself. Let’s say it’s a liver drug you General Electric has teamed up with the pre-eminent stem cell biotech firm in the world to make this happen, and we own that little company in our portfolio.

See the full write-up on this trend in Tomorrow in Review on Jan. 9, 2015.

To review:

  • Immunotherapy
  • Stem cell regenerative medicine
  • Gene editing
  • 3-D printing of organs
  • And better testing of drugsand stem cells.

These could change everything we know about medicine.

Through the ninth of January, Ray Blanco, editor of Technology Profits Confidential, and I will present a special series on these five critical trends for 2015 and what you absolutely need to know before you invest in them.

You won’t want to miss a single day.

Stay tuned.

Stephen Petranek
for The Daily Reckoning

The Daily Reckoning